Austria/Belgium: Schoenherr advises FRI-Invest GmbH and its shareholders on Fluidda's acquisition by Banook

Fluidda, founded in Belgium, is globally recognised for its expertise in computational fluid dynamics and quantitative CT-based imaging to assess lung structure and function. Its proprietary Functional Respiratory Imaging (FRI) platform is widely used to optimise drug development and improve patient outcomes in chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and pulmonary hypertension (PH).

For Banook, a leading global provider of centralised cardiac safety, central imaging and clinical endpoint management services, the acquisition of Fluidda marks a significant milestone in the company’s strategy to diversify and expand into respiratory clinical research and advanced imaging analytics.

By integrating Fluidda's cutting-edge imaging capabilities with Banook's operational excellence in endpoint management and global clinical trial delivery, the combined organisation will offer an unmatched portfolio of scientific, imaging and data-driven services across respiratory and cardiovascular therapeutic areas.

The Schoenherr team advising FRI-Invest GmbH included Thomas Kulnigg (Partner), Clemens Pretscher (Attorney at Law), Niklas Kerschbaumer (Attorney at Law) and Maximilian Czernin (Associate).

Loyens & Loeff advised Fluidda's shareholders on all Belgian law matters relating to the transaction.